US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
AstraZeneca PLC - American Depositary Shares
(NY:
AZN
)
156.90
-0.80 (-0.51%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AstraZeneca PLC - American Depositary Shares
< Previous
1
2
3
4
Next >
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
February 12, 2026
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...
Via
Finterra
Topics
Economy
Intellectual Property
The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges
February 11, 2026
As of February 11, 2026, the corporate landscape is undergoing its most significant transformation in half a decade. After two years of high interest rates and regulatory gridlock that chilled the...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
February 11, 2026
From
AstraZeneca
Via
Business Wire
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
February 10, 2026
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...
Via
MarketMinute
Topics
Artificial Intelligence
Earnings
Economy
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
February 10, 2026
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...
Via
Finterra
Topics
Economy
Intellectual Property
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026
February 10, 2026
Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British...
Via
Finterra
Topics
Artificial Intelligence
Economy
Fraud
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
February 10, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
AstraZeneca results: FY and Q4 2025
February 10, 2026
From
AstraZeneca
Via
Business Wire
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
February 06, 2026
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a...
Via
TokenRing AI
Topics
Artificial Intelligence
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
February 06, 2026
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade...
Via
Finterra
Topics
Economy
Government
Intellectual Property
Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
February 05, 2026
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of...
Via
MarketMinute
Topics
Artificial Intelligence
Earnings
Economy
OAK Family Advisors Sells $4 Million of NICE Stock
↗
February 05, 2026
This software firm delivers AI-driven cloud platforms for enterprise customer engagement and compliance across global markets.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
February 03, 2026
From
AstraZeneca
Via
Business Wire
US Trade Deficit Widens to -$56.8 Billion: A Surprise Drag on GDP Amid AI Infrastructure Surge
February 02, 2026
The U.S. economy faced a sobering reality check last week as the Bureau of Economic Analysis (BEA) released a trade report on January 29, 2026, revealing a deficit that widened far beyond initial...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
World Trade
< Previous
1
2
3
4
Next >
